In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

Researchers from the Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC) ...

The National Psoriasis Foundation issued a new position statement that clarifies the definition of psoriasis disease severity ...

SAN FRANCISCO, CA, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is ...

Incorporating patient-reported outcome measures, such as quality of life, as well as looking into real-world data, is ...

Learn about psoriasis treatment costs, from affordable steroids to costly biologics.

Between 20 and 30 percent of people with psoriasis eventually develop a second, more disabling problem: painful joint inflammation. Known as psoriatic arthritis, it can quietly worsen and, without ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, this condition known as psoriatic arthritis can lead to ...

New research shows risankizumab delivers long-term psoriasis control, with OCT revealing reduced subclinical inflammation.

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

Over 52 weeks of treatment, risankizumab led to significant improvements in both clinical outcomes and optical coherence tomography (OCT) parameters, highlighting the value of long-term therapy ...

An Evening of Jazz & Generosity Returns to Atlanta ATLANTA, GA, UNITED STATES, January 20, 2026 /EINPresswire.com/ ...